Registro exitoso
Cuenta activada
Su cuenta se ha activado con éxito.
Usted ya puede acceder a los últimos contenidos, eventos y recursos en nuestro sitio web.
240
84 results
Kivexa
Sulfato de abacavir-lamivudina<br> VIH
Avodart
Dutasteride<br> Urologia
Xuzal
Levocetirizina<br> Alergía
Epivir
Lamivudina<br> VIH
Ziagen
Abacavir<br> VIH
Malarone
Atovacuona/Proguanil<br> Antiinfecciosos
Flixonase
Propionato de fluticasona<br> Respiratorio
Celsentri
Maraviroc<br> VIH
Fortum
Ceftazidima<br> Antiinfecciosos
Naramig
Naratriptán<br> Sistema Nervioso Central
Zyrtec
Cetirizina dihidrocloruro<br> Alergía
Combivir
Lamivudina-Zidovudina<br> VIH
Zentel
Albendazol<br> Otros
Serevent
Salmeterol<br> Respiratorio
Retrovir
Zidovudina<br> VIH
Información de Seguridad
Al acceder a esta sesión encontrará toda la información sobre Anoro Ellipta y el desafio "Inicie con fuerza
Dosis y Administración
Al acceder a esta sesión encontrará toda la información sobre Anoro Ellipta y el desafio "Inicie con fuerza
Dispositivo
Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.
Impacto Ambiental
Published data showing that Relvar has a lower annual carbon footprint and lower lifecycle contributions than many other asthma devices.
Adherencia
Real-world data showing that Relvar new users were more adherent to, and less likely to discontinue, treatment than new users of other ICS/LABA combinations.
Seguridad
Seguridad
Lo Oculto
Lo Oculto
Casualidad o elección
Casualidad o elección
Dispositivo
Dispositivo
Cambiando a Relvar
A patient case study illustrates how Relvar can address invisible symptoms vs patient perceptions of asthma control with ICS/LABA MART regimens.
Percepción de los pacientes vs. la realidad
Patient case studies showing how patient perceptions of asthma control differ from guideline definitions.
Alcanzando el control del asma
How Relvar can achieve asthma control, using guideline definitions and ACT assessment (includes an external link to the ACT website).
Efectos en el cortisol y el eje HHS
The maximum licensed dose of Relvar does not affect the HPA axis or significantly suppress cortisol levels.
Índice terapéutico
A video explanation of therapeutic index and how Relvar’s good therapeutic index is linked to the high receptor binding affinity of its constituent molecules.
Control duradero
Data showing that Relvar’s unique formulation provides continuous improvements in lung function and anti-inflammatory effects over the 24-h dosing interval.
Tamaño de la partícula
Relvar’s particle size falls well within the optimal range for absorption, a factor in asthma control that is often overlooked.
EL SLS
Relvar efficacy data from the SLS, which included patients with comorbidities and those who were smokers, who would usually be excluded from RCTs.
Calidad de vida
Post-hoc analysis night-time awakening data from three RCTs and AQLQ data showing how patients with uncontrolled asthma can benefit from taking Relvar.
Exacerbaciones
Real-world evidence and clinical trial data reveal how Relvar can reduce the rate of asthma exacerbations vs budesonide/formoterol and ICS, respectively.
Monitoreo de la dependencia de SABA
GINA guidelines state that SABA use > twice weekly suggests poor asthma control. Real-world data vs budesonide/formoterol show how Relvar reduces SABA dependence.
Generalidades
Key Relvar benefits in adults/adolescents with uncontrolled, partially controlled or adequately controlled asthma.
Acerca de la terapia LA
Exclusively created for healthcare professionals to provide information, services and support related to VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine)
Intereses y necesidades del paciente
Exclusively created for healthcare professionals to provide information, services and support related to VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine)
Identificación del paciente
Exclusively created for healthcare professionals to provide information, services and support related to VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine)
Eficacia de ATLAS-2M
Eficacia de ATLAS-2M
Seguridad y tolerabilidad e interacciones farmacológicas
Seguridad y tolerabilidad e interacciones farmacológicas
Resumen
Resumen
VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine) Product Information for Healthcare Professionals
Diseño del estudio ATLAS-2M
Resultados reportados por los pacientes en ATLAS-2M
Resultados reportados por los pacientes en ATLAS-2M
VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine) Product Information for Healthcare Professionals
Inicio
Decodificando Relvar
Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.
Volibris
Ambrisentan<br> Enfermedades Raras
Protección temprana
This page contains an overview of Early protection of Rotavirus disease
Amplia protección y efecto
This page contains an overview of Broad protection of Rotarix vaccination and impact data
Seguridad
This page contains information about safety
Cumplimiento y cobertura
This page contains an overview of compliance and coverage of Rotarix vaccine
Rotavirus
This page contains an overview of the Rotavirus disease
Apoyo a los padres
This page contains parent support materials
Recursos
Recursos
No hubo coincidencias. Intente por favor:
- Revisar la ortografía del término de búsqueda.
- Intente un nuevo término de búsqueda
- Reestablecer o revisar los filtros de búsqueda (si utilizó filtros para esta búsqueda)
Mostrar más
